Endogenous BTG2 expression stimulates migration of bladder cancer cells and correlates with poor clinical prognosis for bladder cancer patients

Tumor Progression and Oncogene Addiction in a PDGF-B-Induced Model of Gliomagenesis

(2015) Filippo Calzolari et al.   NEOPLASIA

Current status of molecular markers for prognostication and outcome in invasive bladder cancer

(2012) Georgios Gakis et al.   BJU INTERNATIONAL

The inhibitors of nucleotide biosynthesis leflunomide, FK778, and mycophenolic acid activate hepatitis B virus replicationin vitro

(2012) Karin Hoppe-Seyler et al.   HEPATOLOGY

High-throughput SNP-based authentication of human cell lines

(2012) Felipe Castro et al.   INTERNATIONAL JOURNAL OF CANCER

Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer

(2012) S E Jalava et al.   ONCOGENE

Breast tumor progression induced by loss of BTG2 expression is inhibited by targeted therapy with the ErbB/HER inhibitor lapatinib

(2011) F Takahashi et al.   ONCOGENE

EZH2 Depletion Blocks the Proliferation of Colon Cancer Cells

(2011) Bettina Fussbroich et al.   PLoS One

Variant Forms of Bladder Cancer: Basic Considerations on Treatment Approaches

(2011) Francesc Pons et al.   Current Oncology Reports

Up-regulation of cell cycle arrest protein BTG2 correlates with increased overall survival in breast cancer, as detected by immunohistochemistry using tissue microarray

(2010) Elin Möllerström et al.   BMC CANCER

Molecular Pathogenesis and Diagnostics of Bladder Cancer

(2008) Anirban P. Mitra et al.   Annual Review of Pathology-Mechanisms of Disease

B Cell Translocation Gene 2 Enhances Susceptibility of HeLa Cells to Doxorubicin-induced Oxidative Damage

(2008) Young-Bin Lim et al.   JOURNAL OF BIOLOGICAL CHEMISTRY